Current Urology Reports

, Volume 8, Issue 5, pp 341–344

Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?

Invited Commentary


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Welch HG, Schwartz LM, Woloshin S.: Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. JNCI 2005, 97:1132–1137.PubMedGoogle Scholar
  2. 2.
    Sakr WA, Haas GP, Cassin BF, et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379–385.PubMedGoogle Scholar
  3. 3.
    Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8–29.PubMedGoogle Scholar
  4. 4.
    Etzioni R, Penson DF, Legler JM, et al.: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94:981–990.PubMedGoogle Scholar
  5. 5.
    D’Amico AV, Whittington R, Schultz D, et al.: Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997, 158:1422–1426.PubMedCrossRefGoogle Scholar
  6. 6.
    Albertsen P, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095–2101.PubMedCrossRefGoogle Scholar
  7. 7.
    Albertsen PC, Hanley JA, Barrows GH, et al.: Prostate cancer and the Will Rogers phenomenon. Natl Cancer Inst 2005, 97:1248–1253.Google Scholar
  8. 8.
    Hanash K, Utz DC, Cook EN, et al.: Carcinoma of the prostate: a 15-year followup. J Urol 1972, 107:450–453.PubMedGoogle Scholar
  9. 9.
    Johansson J, Holmberg L, Johansson S, et al.: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997, 277:467–471.PubMedCrossRefGoogle Scholar
  10. 10.
    Lerner S, Seale-Hawkins C, Carlton CE, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991, 146:1040–1045.PubMedGoogle Scholar
  11. 11.
    Handley R, Carr TW, Travis D, et al.: Deferred treatment for prostate cancer. Br J Urol 1998, 62:249–253.CrossRefGoogle Scholar
  12. 12.
    Adolfsson J, Röströ L, Löhagen T, et al.: Deferred treatment in clinically localized low-grade prostate carcinoma: the experience from a prospective series at the Karolinska Hospital. J Urol 1994, 69:1757–1760.Google Scholar
  13. 13.
    Waaler G, Stenwig AE: Prognosis of localised prostatic cancer managed by “watch and wait” policy. Br J Urol 1993, 72:214–219.PubMedGoogle Scholar
  14. 14.
    Whitmore W, Warner JA, Thompson IM.: Expectant management of localized prostatic cancer. Cancer 1991, 67:1091–1096.PubMedCrossRefGoogle Scholar
  15. 15.
    George NJ: Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1998, 1:494–494.Google Scholar
  16. 16.
    Aus G, Hugosson I, Norlén L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995, 154:460–465.PubMedCrossRefGoogle Scholar
  17. 17.
    Sandblom G, Dufmants M, Varenhorst E: Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000, 56:442–447.PubMedCrossRefGoogle Scholar
  18. 18.
    Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005, 23:8165–8169.PubMedCrossRefGoogle Scholar
  19. 19.
    Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004, 5:101–106.PubMedCrossRefGoogle Scholar
  20. 20.
    McGregor M., Hanley JA, Boivin JF, et al.: Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998, 159:1368–1372.PubMedGoogle Scholar
  21. 21.
    Presti JC Jr: Prostate biopsy: how many cores are enough? Urol Oncol 2003, 21:135–140.PubMedGoogle Scholar
  22. 22.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  23. 23.
    Pound C, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591–1597.PubMedCrossRefGoogle Scholar
  24. 24.
    Draisma G, Boer R, Otto SJ, et al.: Lead times and overdetection due to PSA screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868–878.PubMedCrossRefGoogle Scholar
  25. 25.
    Tönblom M, Eriksson H, Franzén S, et al.: Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122–129.CrossRefGoogle Scholar
  26. 26.
    Choo R, Klotz L, Danjoux C, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664–1669.PubMedCrossRefGoogle Scholar
  27. 27.
    Choo R, DeBoer G, Klotz L, et al.: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001, 50:615–620.PubMedCrossRefGoogle Scholar
  28. 28.
    Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006, 24:46–50.PubMedGoogle Scholar
  29. 29.
    Bill-Axelson A, Holmberg L, Ruutu M, et al.: Radical prostatectomy versus watchful waiting. N Engl J Med 2005, 352:1977–1984.PubMedCrossRefGoogle Scholar
  30. 30.
    Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790–796.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Urology, Professor of SurgeryUniversity of Toronto, and Chief, Sunnybrook & Women’s College Health Sciences CentreTorontoCanada

Personalised recommendations